Climb Bio, Inc. (CLYM) stock
CLYMNasdaqPharmaceutical PreparationsFiscal year ends December 31
$9.30−0.48 (-4.91%)
Close on Nov 18, 2026Market cap $534.16MP/E –Yield –
Climb Bio operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Climb Bio's operating income for the twelve months ending Jun 30, 2026 was -$64.76M. For fiscal 2025 it was -$67.88M. The highest annual figure on record is -$20.93M in fiscal 2020.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$67.88M | – |
| FY2024 | Dec 31, 2024 | -$82.02M | – |
| FY2023 | Dec 31, 2023 | -$40.28M | – |
| FY2022 | Dec 31, 2022 | -$45.14M | – |
| FY2021 | Dec 31, 2021 | -$35.67M | – |
| FY2020 | Dec 31, 2020 | -$20.93M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$15.36M | – |
| Q1 FY2026 | Mar 31, 2026 | -$15.21M | – |
| Q4 FY2025 | Dec 31, 2025 | -$19.30M | – |
| Q3 FY2025 | Sep 30, 2025 | -$14.89M | – |
| Q2 FY2025 | Jun 30, 2025 | -$10.68M | – |
| Q1 FY2025 | Mar 31, 2025 | -$23.02M | – |
| Q4 FY2024 | Dec 31, 2024 | -$10.91M | – |
| Q3 FY2024 | Sep 30, 2024 | -$11.73M | – |
| Q2 FY2024 | Jun 30, 2024 | -$56.37M | – |
| Q1 FY2024 | Mar 31, 2024 | -$3.01M | – |
| Q4 FY2023 | Dec 31, 2023 | -$5.12M | – |
| Q3 FY2023 | Sep 30, 2023 | -$5.00M | – |
| Q2 FY2023 | Jun 30, 2023 | -$6.71M | – |
| Q1 FY2023 | Mar 31, 2023 | -$23.44M | – |
| Q4 FY2022 | Dec 31, 2022 | -$9.55M | – |
| Q3 FY2022 | Sep 30, 2022 | -$8.75M | – |
| Q2 FY2022 | Jun 30, 2022 | -$13.70M | – |
| Q1 FY2022 | Mar 31, 2022 | -$13.13M | – |
| Q4 FY2021 | Dec 31, 2021 | -$10.70M | – |
| Q3 FY2021 | Sep 30, 2021 | -$9.38M | – |
| Q2 FY2021 | Jun 30, 2021 | -$8.71M | – |
| Q1 FY2021 | Mar 31, 2021 | -$6.88M | – |
| Q4 FY2020 | Dec 31, 2020 | -$15.11M | – |
| Q3 FY2020 | Sep 30, 2020 | -$2.26M | – |
| Q2 FY2020 | Jun 30, 2020 | -$1.61M | – |
See a number that looks wrong?